| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | YM-155 | GDSC1000 | pan-cancer | AAC | -0.043 | 0.2 |
| mRNA | Sorafenib | GDSC1000 | pan-cancer | AAC | -0.071 | 0.2 |
| mRNA | tivantinib | CTRPv2 | pan-cancer | AAC | 0.06 | 0.2 |
| mRNA | dacarbazine | CTRPv2 | pan-cancer | AAC | -0.041 | 0.2 |
| mRNA | TGX221 | CTRPv2 | pan-cancer | AAC | -0.048 | 0.2 |
| mRNA | ISOX:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.045 | 0.2 |
| mRNA | QL-XI-92 | GDSC1000 | pan-cancer | AAC | -0.039 | 0.2 |
| mRNA | VAF-347 | CTRPv2 | pan-cancer | AAC | 0.06 | 0.2 |
| mRNA | PD 153035 | CTRPv2 | pan-cancer | AAC | -0.054 | 0.2 |
| mRNA | AG-014699 | GDSC1000 | pan-cancer | AAC | -0.042 | 0.2 |